← All trials
NCT03795272
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2019
- Primary completion
- Sep 1, 2022
- Completion date
- Sep 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nordic Society for Gynaecologic OncologyLead sponsor
- University of TorontoCollaborator
- University of LondonCollaborator
- Katholieke Universiteit LeuvenCollaborator
- North Eastern Germany Society of Gynaecologic OncologyCollaborator
- GSO Global Clinical Research BVCollaborator
- PGOG (Polish Gynaecologic Oncology Group)Collaborator
- Central and Eastern European Oncology GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.